Teva Pharmaceutical Industries has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. The separation is planned to take effect July 1, 2018 subject to receipt of applicable regulatory approvals. No significant (material) net financial transfer between Teva and P&G will result from the dissolution.
— Businesswire

Teva is based in Israel but has Indian and Chinese subsidiaries and operations.

Platinum Partners advised Tevapharm India Private Limited led by a team of partner Ankit Majmudar, associate Ritika Chatterjee.

Goodwin Procter acted as Teva Pharmaceutical Industries’ international advisors.

Cyril Amarchand Mangaldas represented Procter & Gamble.

Primary jurisdiction of deal: Global.

2018-10-08

Deal value: Confidential

This deal report is based on a firm's press release and may be only partially complete. Some firms or names of advisers may be therefore be missing.